Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial

PURPOSE: Docetaxel and abiraterone acetate plus prednisone or prednisolone (AAP) both improve survival when commenced alongside standard of care (SOC) androgen deprivation therapy in locally advanced or metastatic hormone-sensitive prostate cancer. Thus, patient-reported quality of life (QOL) data m...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Rush, Hannah L., Murphy, Laura, Morgans, Alicia K., Clarke, Noel W., Cook, Adrian D., Attard, Gerhardt, Macnair, Archie, Dearnaley, David P., Parker, Christopher C., Russell, J. Martin, Gillessen, Silke, Matheson, David, Millman, Robin, Brawley, Christopher D., Pugh, Cheryl, Tanguay, Jacob S., Jones, Robert J., Wagstaff, John, Rudman, Sarah, O'Sullivan, Joe M., Gale, Joanna, Birtle, Alison, Protheroe, Andrew, Gray, Emma, Perna, Carla, Tolan, Shaun, McPhail, Neil, Malik, Zaf I., Vengalil, Salil, Fackrell, David, Hoskin, Peter, Sydes, Matthew R., Chowdhury, Simon, Gilbert, Duncan C., Parmar, Mahesh K. B., James, Nicholas D., Langley, Ruth E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2022
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7612717/
https://ncbi.nlm.nih.gov/pubmed/34757812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.21.00728
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi